Search Results - "BOGGS, Douglas L"

Cannabis withdrawal symptoms in non-treatment-seeking adult cannabis smokers by Levin, Kenneth H, Copersino, Marc L, Heishman, Stephen J, Liu, Fang, Kelly, Deanna L, Boggs, Douglas L, Gorelick, David A

“…Abstract Background Cannabis withdrawal is not recognized in DSM-IV because of doubts about its clinical significance. Objectives Assess the phenomenon of…”
Get full text

Going up in smoke? A review of nAChRs-based treatment strategies for improving cognition in schizophrenia by Boggs, Douglas L, Carlson, Jon, Cortes-Briones, Jose, Krystal, John H, D'Souza, D Cyril

“…Cognitive impairment is known to be a core deficit in schizophrenia. Existing treatments for schizophrenia have limited efficacy against cognitive impairment…”
Get more information

The effects of cannabidiol (CBD) on cognition and symptoms in outpatients with chronic schizophrenia a randomized placebo controlled trial by Boggs, Douglas L., Surti, Toral, Gupta, Aarti, Gupta, Swapnil, Niciu, Mark, Pittman, Brian, Schnakenberg Martin, Ashley M., Thurnauer, Halle, Davies, Andrew, D’Souza, Deepak C., Ranganathan, Mohini

“…Rationale Preliminary evidence suggests that cannabidiol (CBD) may be effective in the treatment of neurodegenerative disorders; however, CBD has never been…”
Get full text

The 2009 Schizophrenia PORT Psychopharmacological Treatment Recommendations and Summary Statements by Buchanan, Robert W., Kreyenbuhl, Julie, Kelly, Deanna L., Noel, Jason M., Boggs, Douglas L., Fischer, Bernard A., Himelhoch, Seth, Fang, Beverly, Peterson, Eunice, Aquino, Patrick R., Keller, William

“…In light of the large number of studies published since the 2004 update of Schizophrenia Patient Outcomes Research Team psychopharmacological treatment…”
Get full text

Nonresponse to clozapine and premorbid functioning in treatment refractory schizophrenia by Kelly, Deanna L, Feldman, Stephanie, Boggs, Douglas L, Gale, Elizabeth, Conley, Robert R

“…Abstract Introduction It is recognized that early treatment can improve outcomes and generally improve recovery potential for those with schizophrenia. Data…”
Get full text

A Survey of Prescribers' Attitudes, Knowledge, Comfort, and Fear of Consequences Related to an Opioid Overdose Education and Naloxone Distribution Program by Peckham, Alyssa M, Niculete, Maria E, Steinberg, Howard, Boggs, Douglas L

“…The alarming increase in opioid-related fatalities has placed the United States in the midst of an opioid epidemic. In an effort to reduce opioid-related…”
Get full text

Minimal effects of prolonged smoking abstinence or resumption on cognitive performance challenge the “self-medication” hypothesis in schizophrenia by Boggs, Douglas L, Surti, Toral S, Esterlis, Irina, Pittman, Brian, Cosgrove, Kelly, Sewell, R. Andrew, Ranganathan, Mohini, D'Souza, Deepak Cyril

“…Abstract One prominent, long-standing view is that individuals with schizophrenia smoke cigarettes more than the general population to “self-medicate”…”
Get full text

The effects of galantamine on psychopathology in chronic stable schizophrenia by Conley, Robert R, Boggs, Douglas L, Kelly, Deanna L, McMahon, Robert P, Dickinson, Dwight, Feldman, Stephanie, Ball, M Patricia, Buchanan, Robert W

“…Galantamine is an acetylcholinesterase inhibitor and an allosteric modulator of the alpha4beta2 and alpha7 nicotinic receptors. There are several case reports…”
Get full text

Diagnostic criteria for cannabis withdrawal syndrome by Gorelick, David A, Levin, Kenneth H, Copersino, Marc L, Heishman, Stephen J, Liu, Fang, Boggs, Douglas L, Kelly, Deanna L

“…Abstract Objective Cannabis withdrawal occurs in frequent users who quit, but there are no accepted diagnostic criteria for a cannabis withdrawal syndrome…”
Get full text

Reaching for Wellness in Schizophrenia by Kelly, Deanna L., PharmD, BCPP, Boggs, Douglas L., PharmD, MS, Conley, Robert R., MD

“…Coronary heart disease (CHD) is a major cause of mortality in people who have schizophrenia, and it is caused by many factors relating to lifestyle choices,…”
Get full text

The dose-dependent psychomotor effects of intravenous delta-9-tetrahydrocannabinol (Δ9-THC) in humans by Boggs, Douglas L, Cortes-Briones, Jose A, Surti, Toral, Luddy, Christina, Ranganathan, Mohini, Cahill, John D, Sewell, Andrew R, D’Souza, Deepak C, Skosnik, Patrick D

“…Background: Binding studies have demonstrated that levels of the cannabinoid receptor type-1 are highest in the basal ganglia and cerebellum, two areas…”
Get full text

Cigarette Smoking and Mortality Risk in People With Schizophrenia by Kelly, Deanna L., McMahon, Robert P., Wehring, Heidi J., Liu, Fang, Mackowick, Kristen M., Boggs, Douglas L., Warren, Kimberly R., Feldman, Stephanie, Shim, Joo-Cheol, Love, Raymond C., Dixon, Lisa

“…This study examined effects of cigarette smoking on mortality risk in 1213 persons aged 19-69 years with schizophrenia-related psychotic disorders admitted to…”
Get full text

Clinical and Preclinical Evidence for Functional Interactions of Cannabidiol and Δ9-Tetrahydrocannabinol by Boggs, Douglas L, Nguyen, Jacques D, Morgenson, Daralyn, Taffe, Michael A, Ranganathan, Mohini

“…The plant Cannabis sativa, commonly called cannabis or marijuana, has been used for its psychotropic and mind-altering side effects for millennia. There has…”
Get full text

The role of antihistaminic effects in the misuse of quetiapine: A case report and review of the literature by Fischer, Bernard A., Boggs, Douglas L.

“…Recent case reports and case series suggest that the atypical antipsychotic quetiapine has the potential for misuse. This includes drug-seeking behaviors…”
Get full text

Rimonabant for neurocognition in schizophrenia: A 16-week double blind randomized placebo controlled trial by Boggs, Douglas L, Kelly, Deanna L, McMahon, Robert P, Gold, James M, Gorelick, David A, Linthicum, Jared, Conley, Robert R, Liu, Fang, Waltz, James, Huestis, Marilyn A, Buchanan, Robert W

“…Abstract Objective To examine the effect of rimonabant on neurocognitive impairments in people with schizophrenia. Methods Participants entered a 16-week…”
Get full text

Pilot study of Intravenous Nicotine Effects on Cognitive Performance in Schizophrenia by Boggs, Douglas L, Ranganathan, Mohini, Sewell, R. Andrew, Madonick, Steven, D'Souza, Deepak Cyril

Get full text

Effects of the Cannabinoid-1 Receptor Antagonist Rimonabant on Psychiatric Symptoms in Overweight People With Schizophrenia A Randomized, Double-Blind, Pilot Study by KELLY, Deanna L, GORELICK, David A, HUESTIS, Marilyn A, HEISHMAN, Stephen J, WARREN, Kimberly R, BUCHANAN, Robert W, CONLEY, Robert R, BOGGS, Douglas L, LINTHICUM, Jared, FANG LIU, FELDMAN, Stephanie, BALL, M. Patricia, WEHRING, Heidi J, MCMAHON, Robert P

“…Weight gain is a major adverse effect of several second-generation antipsychotic medications. Rimonabant is a cannabinoid-1 receptor antagonist that promotes…”
Get full text

Cannabis withdrawal in chronic cannabis users with schizophrenia by Boggs, Douglas L, Kelly, Deanna L, Liu, Fang, Linthicum, Jared A, Turner, Hailey, Schroeder, Jennifer R, McMahon, Robert P, Gorelick, David A

“…Abstract Background Chronic users of cannabis often report withdrawal symptoms after abstinence from use, but little is known about cannabis withdrawal in…”
Get full text

A Randomized Double-Blind Trial of Atomoxetine for Cognitive Impairments in 32 People With Schizophrenia by KELLY, Deanna L, BUCHANAN, Robert W, CONLEY, Robert R, BOGGS, Douglas L, MCMAHON, Robert P, DICKINSON, Dwight, NELSON, Matthew, GOLD, James M, BALL, M. Patricia, FELDMAN, Stephanie, FANG LIU

“…Currently available antipsychotic medications offer only modest, if any, effects on cognitive performance in people with schizophrenia. Treatments that would…”
Get full text

Psychoactive Substance Use by Adults With Schizophrenia Before and During Cannabis Withdrawal by Koola, Maju Mathew, Kelly, Deanna L, McMahon, Robert P, Boggs, Douglas L, Liu, Fang, Gorelick, David A

Get more information